SGEN Seattle Genetics Inc

Seattle Genetics Inc is a biotechnology company. The company is focused on development and commercialization of targeted therapies for the treatment of cancer. Its products are ADCETRIS (brentuximab vedotin) US and ADCETRIS (brentuximab vedotin) Canada.

$142.89  -1.58 (-1.09%)
As of 04/09/2021 15:59:59 EST     IEX book   CBOE book

Security Information
Category1:  US Equity
Category2:  Common stocks
Category3:  Large cap
GICS sector:  Health Care
Industry:  Biotechnology
Index country:  USA
Country of incorporation:  USA
IPO date:  03/07/2001
Outstanding shares:  181,305,871
Average volume:  1,013,240
Market cap:   $25,899,543,672
Current dividend yield:  0.00%
All SEC filings:     SEC Edgar Online
Quarterly filings:   10-Q
Annual filings:      10-K
CUSIP:    81181C104
ISIN:        US81181C1045
Sedol:      BLPK4D2
Valuation   (See tab for details)
PE ratio:   42.20
PB ratio:   7.41
PS ratio:   11.90
Return on equity:   17.59%
Net income %:   28.21%

2021 © Stock Market MBA, Inc. Terms of use | Privacy policy